cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Relmada Therapeutics Inc
3 own
3 watching
Current Price
$0
$-0.08
(-2.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
84.58M
52-Week High
52-Week High
38.68
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization84.58M
icon52-Week High38.68
icon52-Week Low1.81
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Relmada Therapeutics Inc do?
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Read More
How much money does Relmada Therapeutics Inc make?
News & Events about Relmada Therapeutics Inc.
PR Newswire
1month ago
RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws PR Newswire...
PR Newswire
1month ago
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc. RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities...
Business Wire
1month ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (Relmada or the Company) (NASDAQ: RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued...
Globe Newswire
1month ago
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. (Relmada or the Company) (NYSE: RLMD) concerning possible violations of federal securities laws. Before market opened on October 13, 2022, Relmada ...
PR Newswire
2 months ago
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 PR Newswire CORAL...
Frequently Asked Questions
Frequently Asked Questions
What is Relmada Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Relmada Therapeutics Inc shares?
plus_minus_icon
How can I buy Relmada Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Relmada Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Relmada Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Relmada Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Relmada Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Relmada Therapeutics Inc?
plus_minus_icon
What percentage is Relmada Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Relmada Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.08
(-2.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00